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with more than 2 million affected. The hygiene hypothesis suggests improved sanitation and eradication of
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Background: Inflammatory bowel disease (IBD) refers to a group of disorders causing chronic 
relapsing inflammation of the gastrointestinal tract. The highest incidence of IBD occurs in 
Europe and North America with more than 2 million affected. The hygiene hypothesis suggests 
improved sanitation and eradication of parasitic infections in industrialized nations may explain 
the epidemiologic predilection of disease. Helminths are parasitic worms that diminish immune 
responsiveness and inflammation in animal studies. Epidemiologic data also suggests that 
helminths have a protective role in the development of IBD. Trichuris suis is a type of helminth 
traditionally found in pigs. In humans, it has never been found to cause disease.  Is Trichuris suis 
helminth therapy (TSO) effective and safe in the treatment of inflammatory bowel disease? 
 
 
Methods: An exhaustive literature search to identify relevant published papers was conducted 
using the databases Medline-OVID, CINAHL, Web of Science, and PubMed using the 
keywords: inflammatory bowel disease, Crohn’s disease, ulcerative colitis, helminths, and 
Trichuris. Articles with primary data were included if they addressed the safety and/or efficacy 
of Trichuris suis ova therapy for IBD. Relevant articles were assessed for quality using the 
GRADE criteria.  
 
 
Results:  Two randomized controlled trials and two observational case series reports fit the 
inclusion criteria.  All of the studies demonstrated clinical improvement in the indices 
traditionally used to monitor disease activity in Crohn’s disease and ulcerative colitis. No 
adverse effects were associated with TSO therapy.  
 
Conclusion: Epidemiologic data, animal studies, and the abovementioned human trials all 
demonstrate that TSO is an effective and safe therapy in the treatment of IBD. However, current 
clinical trials have released preliminary data that show lack of efficacy. Until data from these 
trials can be further evaluated, a strong recommendation for TSO cannot not be made. 
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The Efficacy and Safety of Trichuris suis 
Helminth Therapy in the Treatment of 
Inflammatory Bowel Disease 
BACKGROUND 
 Inflammatory bowel disease (IBD) refers to a group of disorders causing chronic 
relapsing inflammation of the gastrointestinal tract. The two forms of IBD, ulcerative colitis 
(UC) and Crohn’s disease (CD) are categorized based on the degree and location of intestinal 
inflammation.  Ulcerative colitis is characterized by diffuse mucosal inflammation of the rectum 
and colon while Crohn’s disease can affect any part of the gastrointestinal tract, causing patchy 
transmural inflammation.1 The symptoms of IBD are greatly varied and include abdominal pain, 
diarrhea, weight loss, rectal bleeding, and fever. Both diseases are characterized by periods of 
symptomatic flare-ups and remission. While the precise cause of IBD is unknown, it is thought 
by researchers that the disease results from a combination of defects in host interactions with 
intestinal microbiota, intestinal epithelial dysfunction, and aberrant mucosal immune responses 
to contents within the intestine.2 Genetic and environmental factors are also thought to play an 
important role in the pathogenesis of IBD.3   
 The highest incidence of IBD occurs in industrialized Western countries with more than 2 
million affected people in Europe and North America.4 In the last century, there has been a 
steady increase of IBD in developed countries.3 Originally developed by Stachan,5 the “hygiene 
hypothesis” theory suggests a relationship between a higher incidence of immune mediated 
disease with improved amenities, smaller family size, and higher standards of personal 
cleanliness of westernized societies. In the 1990s, Weinstock and Elliot suggested that children 
raised in extremely hygienic environments are predisposed to immunological diseases later in 
life.  Their “IBD hygiene hypothesis” further speculated that in hygienic environments there is a 
lack of exposure to intestinal parasites called helminths, which has contributed to the 
development of IBD.6  
Humans have been co-evolving with parasites for most of history. Found in greater than 
one-third of the world’s population, helminths are a broad group of parasitic worms spread 
through contact with contaminated soil, water, or food.7 Researchers conducted studies8 on 
animals based on the idea that helminths may have a useful role in the responses initiated by the 
immune system. Initial investigations into the therapeutic use of helminths showed both a 
protective and therapeutic benefit of helminths given to colitis inflicted laboratory mice. 
Epidemiological data9  show an inverse relationship between the incidence of IBD and helminth 
exposure, suggesting that helminth infection may have a protective role and prevent IBD from 
developing.  In their South African case control study, Chu et al10 found that childhood helminth 
infection was protective against the development of IBD.  
Helminthic infections are thought to alter the host immune response in several ways. Joel 
Weinstock is a medical doctor from Tufts University and recognized worldwide for his extensive 
research in the study of helminths for the treatment of IBD. He explains that helminths cause 
changes that induce activation of regulatory T cells involved in dampening immune responses 
and curbing autoimmunity. They also influence other cells that prevent the activation of effector 
T cells which lead to inflammation and disease. Finally, the worms appear to influence the 
intestinal microflora by altering bacterial composition and promoting bacteria responsible for 
maintaining intestinal health.11 Based on the successful use of helminths in animal models, 
Weinstock and colleagues4 searched the helminths for a species that could be therapeutically 
used in humans. They found Trichuris suis, a type of whipworm found in pigs and closely related 
to the human whipworm Trichuris trichuria. This microscopic parasite was thought to be an 
ideal candidate for human use based on the characteristics that it does not migrate beyond the 
intestines, reproduce within its host, or transmit from one human host to another. Furthermore, 
pig farmers that have been chronically exposed to the T. suis parasite never develop human 
disease.12 The parasite can be harvested from pathogen-free pigs and administered to human 
patients through ingestion of Trichuris suis ova (TSO).   
Epidemiologic studies and animal models support the relationship of helminths and the 
development of IBD.  Safety profiles encourage the use of T. suis as a possible therapeutic use of 
helminth infection in human hosts. Is Trichuris suis helminth therapy effective and safe in the 
treatment of inflammatory bowel disease? 
METHODS 
 
 An exhaustive medical literature search to identify potentially relevant published papers 
was conducted using the databases Medline-OVID, CINAHL, Web of Science and PubMed 
using the keywords: inflammatory bowel disease, Crohn’s disease, ulcerative colitis, helminths, 
and Trichuris. The search was further narrowed to include articles in the English language and 
human studies.  The bibliographies of included articles were also screened for additional relevant 
sources. Articles with primary data were included if they addressed the safety and/or efficacy of 
Trichuris suis therapy for inflammatory bowel conditions. Relevant articles were assessed for 
quality, validity, and risk of bias using the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE).13 A search of the National Institute of Health clinical 
trials website revealed two ongoing trials investigating the use of Trichuris suis for Crohn’s 
disease.  
RESULTS 
 
 The initial search generated 52 articles for review. Duplicates were removed and the 
remaining articles were screened for primary data studies. Four remaining studies met inclusion 
criteria.  Two studies are randomized control trials14,15 and two are observational case series 
reports.16,17  See Table 1. 
Sandborn et al (2013) RCT 
 This randomized, double-blind, placebo-controlled trial14 evaluated the safety and 
tolerability of single, escalating doses (500, 2500, and 7500) of TSO therapy versus placebo in 
patients with Crohn’s disease. Thirty-six patients between the ages of 20-54 years were recruited 
from six different US sites and split into three different cohorts of 12. The treatment to placebo 
ratio was 3:1 respectively, resulting in 27 patients receiving therapy and 9 receiving placebo.  
The first cohort received 500 TSO or placebo. Upon completion of a 2-week follow-up for 
cohort 1, the second cohort received 2500 TSO or placebo. After 2 weeks of follow-up for cohort 
2, the final cohort received 7500 TSO versus placebo. In this manner the therapy could be 
investigated for the safety and tolerability of different doses of therapy. Safety and tolerability 
were evaluated by monitoring the emergence of treatment emergent adverse events (TEAEs) 
during the study period of 14 days and at month 1, 2 and 6 for follow-up.14  
 Patients with confirmed Crohn’s disease of at least 3 months duration and between the 
ages of 18-55 years old were invited to participate in the study. Concomitant use of oral 
sulfasalazine, mesalazine (5-ASA), mesalazine derivatives, oral prednisone, and azathropine or 
mercaptopurine was allowed if patients were on stable doses. Exclusionary criteria included 
patients with anemia, leukopenia, thrombocytopenia, pregnancy or breast feeding, ulcerative 
colitis, indeterminate colitis, ulcerative proctitis, bowel surgery within 6 months, resection of > 
50cm of the ileum, ileostomy, colostomy, or septic complications. Also excluded were patients 
with gastrointestinal abscess, perforation, active draining fistulae considered clinically 
significant, perianal lesions, history of colorectal cancer or colorectal dysplasia, parentral or tube 
feeding, and evidence of infectious colitis or other enteric pathogens at screening.14  
 Randomization was provided by the drug packaging vendor and employed a software 
algorithm to allocate patients to the different cohorts based on study design. Dose suspensions 
were given in amber glass containers with black outer lacquer to conceal the contents from 
patients and researchers, thus preserving blinding. The gastrointestinal symptoms of helminth 
infection may closely resemble the intestinal manifestations of IBD.  To help differentiate the 
source of symptoms, researchers performed comprehensive medical histories to establish a 
baseline in each patient before starting therapy. Overall characteristics of the two groups were 
similar; however, the mean age of the placebo group was 10 years older than the treatment group 
and there was some variation in the pre-treatment symptoms of each group. All patients 
completed the 14-day follow-up period.  Five patients discontinued during the 6-month follow-
up.14  
 Analysis of TSO therapy including all of the combined doses illustrates TSO as generally 
well tolerated and associated with a relative risk reduction of 16.7%. In the initial 14-day follow-
up period, 10/27 (37%) TSO patients (3 in TSO 500, 1 in TSO 2500 and 6 in TSO 7500) and 4/9 
Placebo patients (44.4%) experienced TEAEs.14 The most commonly reported adverse events 
involved gastrointestinal complaints such as diarrhea, nausea, and vomiting. There was no 
evidence of a dose dependent relationship to these events. While the TSO 7500 had the highest 
incidence of TEAEs (66.7%), the TSO 2500 had a TAEAs event rate lower than both the placebo 
and TSO 500 groups (11.1%). In addition, the authors found no significant TAEAs and relatable 
dose relationships during the six month follow-up. Upon study completion, there was no 
evidence of parasite or ova in any patient stool sample.14  
Summers et al (2005) RCT 
This was a randomized, double-blind, placebo-controlled trial15 in which the primary 
outcomes were to determine the efficacy and safety of TSO therapy in patients with ulcerative 
colitis versus those receiving placebo therapy. The trial was conducted by the University of 
Iowa’s Center for Digestive Diseases and elected private practices in Iowa.  The trial enrolled 54 
adult patients, ages 18-72 years old with active colitis defined by an Ulcerative Colitis Disease 
Activity Index (UCDAI) score of at least four.  The index is a tool used to assess the severity of 
disease in patients with ulcerative colitis. It has four components (stool frequency, rectal 
bleeding, mucosal appearance, and the physician’s rating of disease activity). The Simple Index, 
or Simple Clinical Colitis Disease Activity Index (SCCDAI) was used as a secondary index to 
evaluate disease activity through five criteria (day and night stool frequency, urgency of 
defecation, blood in the stool, general wellbeing, and extra colonic features). 15 
 Included patients were allowed to use concurrent UC anti-inflammatory oral medications 
such as sulfasalazine, mesalamine, prednisone, azathiprine, or 6-mercaptopurine as long as their 
dose and length of use fit within the study parameters. Inclusion also required an assessment of 
laboratory parameters such as complete blood count (CBC), anemia profile, and liver and kidney 
function.  Female patients were required to use birth control and have a negative pregnancy test 
upon study entry. Patients were deemed ineligible for a UCDAI score <4, the presence of 
fulminant colitis, an expected blood transfusion need for GI bleed, or the presence of peritonitis. 
Additionally, patients were excluded if stools contained enteric pathogens or Clostridium 
difficile; received treatment in the past 12 weeks included cyclosporine, methotrexate, or 
immunomodulatory agents other than azathropine/6-MP; received treatment in the last 2 weeks 
included antibiotics, antifungal, or antiparasitic medications; there was the presence of active 
hepatitis C, cytomegalovirus, herpes simplex, or immunodeficiency virus; there was a history of 
cancer; other clinically significant diseases were present that could interfere with protocol 
compliance or interpretation of the results; or there was a history of chemical abuse.15  
 Fifty-four patients were randomized via a random set of numbers. Thirty patients 
received oral TSO 2500 and 24 received placebo at 2 week intervals for 12 weeks.  A person not 
involved in the investigation performed randomization and preparation of the vials. The vials 
containing TSO and placebo were disguised with charcoal and phosphate buffered saline to 
maintain blinding.  No patients were lost to follow-up, however, two were withdrawn due to 
protocol violation. Double-blinding was maintained until study completion. The baseline 
characteristics of the two study groups revealed no significant differences.15  
 The primary measure of efficacy was a reduction of the UCDAI score by 4 or more 
points. Clinical remission was a secondary endpoint, defined as UCDAI < 2.  Additionally, 
researchers evaluated safety by searching for any side effects or complications that could be 
attributed to the therapy, significant changes to baseline hematological or biochemical measures, 
including hepatic and renal profiles and presence of mature parasite or ova in stool. 15  
 Patients were analyzed using intention to treat. TSO therapy for the treatment of 
ulcerative colitis showed a significant response (UCDAI reduction of > 4 points) when compared 
to patients receiving placebo (43.4% vs. 16.7% respectively, RR=2.6, NNT=4). The mean 
UCDAI score went from 8.77 + 0.35 to 6.1 + 0.61 (p 0.0004) in the TSO group. The SCCDAI 
score of the TSO treatment group was also found to be significant at week 10 (p=0.0736) while 
placebo patients did not show significant change. Conversely, the number of patients achieving 
clinical remission was not significant. Only 3/30 TSO patients and 1/24 placebo patients 
achieved a UCDAI between 0-1.15 
No adverse events were experienced that could be attributed to the TSO treatment.  Also, 
there were no significant changes to the baseline hematological and biochemical markers. 
Finally, there was no evidence of Trichuris suis identified in the stool samples of any patients.15  
The authors state that TSO therapy given every 2 weeks is effective to reduce the 
symptoms associated with UC.  They also suggest that this treatment warrants further 
investigation. Studies with larger sample sizes and the use of different dosages may help broaden 
the understanding of TSO therapy.15 
Summers et al (2005) Case Series 
 This study16 is the first of two observational case series reports included in this review. 
Performed in 2005, this was a 24-week open label study investigating the safety and possible 
efficacy of TSO therapy in adult patients with diagnosed Crohn’s disease. Patients were recruited 
by the University of Iowa and eligible for study inclusion if their Crohn’s Disease Activity Index 
(CDAI) score was between 220 and 450, correlating with moderate disease activity. The CDAI is 
considered the gold standard of clinical trials for measuring the disease activity of patients with 
Crohn’s disease.  Patients also continued use of concurrent Crohn’s medications like mesalamine 
or derivatives, oral prednisone, azathioprine, or 6-mercaptopurine if they had been using the 
medication for a specified period of time at stable dose. Laboratory measures including CBC, 
hepatic and renal profiles, and stool samples were examined for any abnormalities that would 
lead to exclusion. Further exclusionary criteria included history of ileostomy, colostomy, 
resection >50cm, obstructive symptoms, or anticipated need for surgery. Patients were also 
excluded if recently treated with immunomodulatory agents, antibiotics, antifungal, or 
antiparasitic medications.16 
 Efficacy was investigated by measuring disease activity through the use of the CDAI. 
Significant response was defined as a decrease in the CDAI >100 points or if the CDAI dropped 
below 150. A CDAI score of 150 correlated with disease remission. Twenty-nine patients were 
recruited and ingested TSO 2500 every 3 weeks for a period of 24 weeks. Their mean CDAI 
score at entry was 294. No patients were lost to follow-up; however, five patients withdrew from 
the study before completion.16  
 Data analysis at 24 weeks demonstrated a significant response (drop in CDAI>100 points 
or CDAI <150) in 23/29 (79.3%) of involved patients.  Also notable was the high rate of patients 
experiencing remission, with 21/29 (72.4%) achieving a CDAI score below 150.  Of those 
patients that responded to therapy, the mean CDAI improvement was 187.2 points.  None of the 
patients developed any adverse reactions or new symptoms during the study period. Laboratory 
data demonstrated no significant differences to baseline levels and there was no indication of 
parasite or ova in patient stool samples.16  
 The authors suggest that the results of this trial lend evidence to TSO as a well-tolerated 
and effective form of therapy for Crohn’s disease.  However, they acknowledge the possibility of 
placebo effect due to the open label nature of this study.  They also postulate the confounding 
effect of concurrent use of Crohn’s medications as their subset analysis did indicate that those 
patients had better outcomes compared with those not using concurrent immunosuppressive 
therapy. They recommend further clinical trials involving blinding and control groups.  16  
 
 
Summers et al (2003) Case series 
 The last study reviewed was an observational open label case series report17 involving 
seven patients with IBD. The primary aim of this study was to investigate whether a single dose 
of TSO 2500 was safe for IBD patients and assess the effect of this therapy on disease activity 
and quality of life. Four patients with active CD and 3 patients with UC were enrolled and 
followed every 2 weeks for a total of 12 weeks.  Eligible patients were at least 18 years of age 
and needed a diagnosis of UC or CD confirmed through colonoscopy or sigmiodoscopy. Female 
participants had to be non-pregnant and using contraceptives. Patients were allowed to continue 
concurrent medical therapy such as prednisone, antibiotics, 5-aminosalicylates, azathropine, or 6-
mercaptpurine as long as the doses were stable for a designated length of time and the dosage 
was not changed during the study timeframe. Exclusionary criteria included patients with 
fulminant colitis or a CDAI <220, ileostomy or colostomy, bowel resection >100cm, or 
anticipated need for surgery. Patients were also excluded if they had concurrent systemic 
diseases, history of cancer, drug or alcohol abuse, or pathogens in stool samples.  Due to the 
small number of patients in the study, the baseline characteristics of those included were quite 
varied.17 
Disease activity was monitored using the SCCAI, CDAI, and the Inflammatory Bowel 
Disease Quality of Life Index (IBDQ). Clinical remission correlated with a reduction in the 
CDAI to <150 for patients with CD, an SCCAI score < 4 for UC patients and an increase in the 
IBDQ to >170 points for all patients. Safety was evaluated through baseline and regular 
monitoring of laboratory tests every 2 weeks. Of the seven that participated, six patients (three 
UC and three CD) achieved remission during the 12 weeks according to the above indices.  On 
average, remission lasted 8 weeks for the abovementioned patients.  One CD patient did not 
achieve remission, yet her CDAI score did drop 153 points during treatment. During the 12 
weeks study period, there was no report of adverse events that could be attributed to the study 
agent and baseline laboratory parameters did not significantly change.17  
As a secondary endpoint, four of the patients in this study were also included in 
maintenance period testing to investigate the safety of repetitive doses after the initial 12-week 
study.17 They were each given TSO 2500 every 3 weeks for varying amounts of time. All of the 
patients included in the maintenance period dosing saw improvements to their disease activity. 
Of these 4 patients, 3 entered remission for a period longer than 1 year, indicating that multiple 
doses may prolong remission.  The authors ascertain that no significant complications or adverse 
effects were caused from multiple doses of TSO 2500 during this period.17  
The authors concluded that although this study is greatly limited by sample size, lack of 
blinding, and control group, they are nonetheless encouraged by the improvement witnessed in 
this study.  They support further exploration of TSO therapy using a larger double-blind, 
placebo-controlled study.17 
DISCUSSION 
 
Crohn’s disease and ulcerative colitis are severe, debilitating, and chronic diseases associated 
with substantial clinical and economic costs. In the United States, the annual cost of treating IBD 
is estimated at $6.3 billion.18 Costs associated with missing time from work for individuals with 
IBD is also significant, amounting in $249 million each year.19 While there are medications 
available that aid in the symptomatic management of UC and CD, there are no cures. Standard 
therapies include systemic corticosteroids, locally acting steroids, aminosalicylates like 5-ASA 
and sufasalazine, immunomodulators, methotrexate, and biologic therapies such as infliximab.20 
Many of these therapies come with hefty price tags and the run risk of serious, even life-
threatening side effects.  Furthermore, considerable portions of patients suffering from IBD are 
refractory to modern pharmaceutical therapies.  There is a great need to explore safer, more 
effective, and less costly treatment options for patients with this condition.  
With their ability to modulate the inflammatory responses of an overzealous immune 
system, helminths may be the answer in the search for more effective therapies. Collectively, the 
studies in this review all support the use of TSO in the treatment of IBD. The randomized, 
double-blinded, placebo-control clinical trial by Sandborn et al14 demonstrated no increase in 
complications or adverse events associated with increasing doses of TSO therapy in patients with 
Crohn’s disease. Although the study had good methodology, it is limited due to the use of a 
small sample size of 36 participants and inconsistency with the prognostic imbalance of pre-
treatment symptoms and mean age.  Individuals receiving TSO 7500 tended to exhibit slightly 
worse pre-treatment symptoms when compared with the other groups, while TSO 500 patients 
fared better in their pre-treatment symptoms severity.14 This inconsistency could help explain the 
high incidence of TEAEs within the TSO 7500 with 66.7% of individuals experiencing 
symptoms. However, no dose response relationship was found based on the analysis showing 
that placebo had more events than both TSO 500 and TSO 2500.  Overall, this study found that 
helminth therapy was associated with a decreased chance of having a TEAE when compared 
with placebo (RRR 16.7%) and TSO 2500 had the least TEAEs of any dose.14  
A dose of TSO 2500 was also investigated by Summers et al (2005) RCT15 in their 
randomized, double-blind, placebo-controlled study. In addition to safety, they were primarily 
interested in the effectiveness of TSO therapy in patients with UC. Their results showed 
significant benefit in disease activity for those using TSO therapy compared with placebo in 
individuals with ulcerative colitis (RR 2.6, NNT=4). This study had good methodology but had 
some minor limitations. A shortcoming of this study was the lack of statistical significance for 
their secondary endpoint of clinical remission (UCDAI < 2).  The authors simply state that there 
were few remissions without listing further data for analysis. The study also has serious 
imprecision as the sample size is small. Overall, the results of this study somewhat support the 
efficacy of this non-traditional therapy.  
Paving the way for the abovementioned randomized control trials, Summers and 
colleagues conducted smaller, observational case series reports16,17 to investigate the safety and 
tolerability of TSO 2500. These two studies were the first attempts to explore the use of TSO 
therapy in humans with IBD. Both studies are of very low quality due to small sample sizes and 
the fact that they were case series reports. In both studies there is a greater potential for placebo 
effect based on the idea that patients were aware they were receiving helminth therapy. In 
Summers et al (2005) case series,16 there was a significant improvement in the disease activity of 
patients with Crohn’s disease receiving TSO therapy with 79% of patients achieving a 100 point 
reduction in their CDAI or a score <150. Moreover, 72% of patients also achieved remission 
within the 24-week study period.  In their 2003 pilot study,17 Summers et al also showed a 
significant response to TSO therapy with all patients experiencing significant reductions in the 
scales used to assess disease activity.  Prior to TSO therapy, all of the patients selected for this 
study had been refractory to conventional medical therapy. Six of these seven patients achieved 
remission.  These results strongly support the use of TSO therapy in IBD patients, especially in 
those that have been refractory to traditional pharmacological therapy.  
In addition to efficacy, safety of TSO therapy is a very important outcome when 
considering use in humans.  In many parts of the world, helminth infection is associated with 
significant morbidity. According to the World Health Organization,21 morbidity is related to the 
number of worms harbored, with heavier infections causing a myriad of symptoms including 
abdominal pain, diarrhea, weakness, anemia, and impaired cognitive and physical development. 
All four of the studies included in this review demonstrated no statistical increase in adverse 
events or complications associated with TSO therapy. There was no worsening of standard 
laboratory data and no observable presence of ova or parasite found in any of the stool samples 
collected for investigation.14-17  
Currently, there are two large-scale clinical trials investigating the use of TSO for the 
treatment of Crohn’s disease. The purpose of the TRUST-1 study22 is to evaluate the safety and 
efficacy of TSO 7500 in a randomized, double-blinded, placebo-controlled 12-week trial. 
Researchers enrolled 250 individuals suffering from mild to moderate Crohn’s disease. The 
study is ongoing and preliminary results show that the study did not meet its primary endpoint of 
improving response or secondary endpoint achieving remission. The European TRUST-2 study23 
is a multi-center randomized control trial to evaluate three different doses of TSO in patients 
with Crohn’s Disease. In late 2013, on the recommendation of an independent data monitoring 
company, this trial was terminated due to lack of efficacy.24 The primary endpoint of response 
and secondary endpoint of remission were not met.  Since the information gained from these 
trials appears to conflict with the data supported by the four articles included in this review, only 
a weak recommendation can be made in using TSO therapy when addressing IBD symptoms.   
CONCLUSION 
 
Inflammatory bowel disease appears to result from a combination of genetic and 
environmental factors that generate an inappropriate immune response. Through complex 
interactions with their host’s immune system, helminths seem to down-regulate the inflammatory 
immune response. The hygiene hypothesis speculates that exposure to helminths could help 
protect from the development of diseases like Crohn’s and ulcerative colitis. Epidemiologic data, 
animal studies, and the four human trials evaluated above demonstrate that TSO therapy may 
have a positive effect on disease activity, while also appearing safe for use in humans.  
However, when considering the evidence, the overall quality of the combined articles is 
low.  This is due to the inherent nature of observational studies as well as the small sample sizes 
used in each trial. Furthermore, the recent preliminary data released from larger phase two 
clinical trials suggests that TSO might not be the answer that many are hoping for.  Nevertheless, 
the generous safety profile of this investigational drug and its use in patients refractory to 
traditional pharmacologic treatments warrants further exploration.  
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Table I. Characteristics of Reviewed Studies, GRADE Profile 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
   
a Lack of prognostic balance at the beginning of the Sandborn et al trial14  and both observational studies16,17 did not have control populations 
b Small sample sizes 
c The Summers et al (2005) RCT15 did not report data consistently 
 
  
Quality Assessment 
 Downgrade Criteria 
Quality Importance No. of 
Studies 
Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Reduction of Disease Activity 
 
3 
 
1 RCT 
2 Observational 
 
 Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
No bias 
likely 
Low Critical 
Remission 
3 
1 RCT 
2 Observational 
 
Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
Serious 
inconsistenciesc 
No bias 
likely 
Very Low Critical 
Adverse Drug Reactions of Complications Attributable to the Therapy 
4 
2 RCT 
2 Observational 
 
Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
No bias 
likely 
Low Important 
Significant Changes to Standard Laboratory Analysis of Hematological and Biological Markers 
3 
1 RCT 
2 Observational 
 
Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
No bias 
likely 
Low Important 
Presence of Parasite or Ova in Stool Upon Study Completion 
3 
2 RCT 
1 Observational 
 
Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
No bias 
likely 
Low 
Less 
Important 
 
 
Table 2. Sandborn et al RCT14 Summary of Findings 
 
 
Table 3. Summers et al (2005) RCT15 Summary of Findings 
Outcome TSO 2500 Control  
Group 
Relative Risk NNT P-value 
Efficacy: 
(UCDAI decreases  
by >4) 
 
13/30 
(43.3%) 
 
4/24 
(16.6%) 
 
2.6 
 
4 
 
Remission:  
(UCDAI < 2) 
**no numbers given, authors stated as insignificant 
UCDAI 0-1 10% 4%   Not 
significant 
 
 
Table 4. Summers et al (2005) Case Series16 Summary of 
Findings 
Outcome TSO 2500 
Efficacy:  
(CDAI decreases  
> 100 points or 
CDAI score <150) 
 
23/29 
(79.3%) 
Remission:  
CDAI <150 
21/29 
(72.4%) 
 
 
Table 5. Summers et al (2003) Case Series17 Summary of 
Findings 
Outcome TSO 2500 
Remission:  
IBDQ >170 
6/7 
(85.7%) 
Remission: 
CDAI <150 
3/4 
 (75%) 
Remission: SCCAI <4 3/3  
(100%) 
Outcome TSO 500 TSO 2500 TSO 7500 TSO total Control 
Group 
Relative 
Risk 
Reduction 
TEAEs 3/9  
(33.3%) 
1/9 
(11.1%) 
6/9 
(66.7%) 
10/27 
(37% 
4/9 
(44.4%) 
16.7 
 
